Clinical trials: Disease, Acute
Acute Myeloid Leukemia
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
The trial is a multi-centre, open-label, safety and tolerability extension trial to the IPH2101-101 (previously NN1975-1733) first human dose trial completed with a larger subject pool at an optimal dose level.
- Trial name
- NCT01256073
- Testing
- IPH2101
- Where
- 6 sites in France
- Volunteers
- 21 people
- Sponsor
- Innate Pharma
Malaria
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be…
- Trial name
- NCT01361269
- Testing
- Fosmidomycin and clindamycin
- Where
- Gabon
- Volunteers
- 100 people
- Sponsor
- Zentopharm GmbH
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Duloxetine Versus Paroxetine for Major Depression
To determine if duloxetine works just as well as paroxetine in the treatment of major depressive disorder.
- Trial name
- NCT00489775
- Testing
- Duloxetine, Paroxetine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Candidiasis, Vulvovaginal
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast infection).
- Trial name
- NCT01891331
- Testing
- VT-1161, Fluconazole
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Viamet
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Brain Ischemia, Stroke
Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke
This study will examine if DP-b99 can improve neurological function (for example strength and coordination) in the 3 months after an acute stroke
- Conditions
- Brain Ischemia, Stroke, Cerebrovascular Disorders
- Trial name
- NCT00190047
- Testing
- DP-b99
- Where
- 22 sites in Germany, Israel
- Volunteers
- 150 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke
MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke
This study evaluates the efficacy of investigational device named Stroke Onset Time Artificial Intelligence(AI) (Model name:NNS-SOT).
- Trial name
- NCT06160726
- Where
- South Korea
- Volunteers
- 474 people
- Sponsor
- Nunaps Inc
Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+)…
- Trial name
- PACE (NCT01207440)
- Testing
- Ponatinib
- Where
- 42 sites in Australia, Belgium and 9 more
- Volunteers
- 449 people
- Sponsor
- Ariad Pharmaceuticals
Acute Myeloid Leukemia, Relapsed Adult AML
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML.
- Trial name
- NCT03932318
- Testing
- Lintuzumab-Ac225, Venetoclax, Azacitidine
- Sponsor
- Actinium Pharmaceuticals
Acute Coronary Syndrome
Clinical Study to Validate the Use of a New Point of Care Troponin I Test
This trial is designed as a prospective, multi-center, observational study of "all-comers" eligible adult subjects presenting to participating emergency departments with symptoms suggestive of acute coronary syndrome (ACS)
- Trial name
- NCT02620397
- Where
- 14 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Trinity Biotech
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Benign Prostatic Hyperplasia
Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II
A single-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis following prostate resection using the AQUABEAM for treatment of LUTS resulting from BPH.
- Trial name
- AHA II (NCT03125889)
- Testing
- AquaBeam System
- Where
- India
- Volunteers
- 11 people
- Sponsor
- PROCEPT BioRobotics
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Biomarkers, Acute Kidney Injury
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of…
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- Trial name
- VENTURE (NCT07893223)
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nutromics
Acute Coronary Syndromes
ALIGN-ACS Pilot Study
The goal of this observational study is to evaluate the diagnostic performance of the HeartBeam ECG System for detection of acute coronary syndrome.
- Trial name
- ALIGN-ACS (NCT07715474)
- Testing
- ECG
- Where
- Serbia
- Volunteers
- 120 people
- Sponsor
- HeartBeam, Inc.
Leukemia, Myelomonocytic, Acute
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy…
- Trial name
- NCT00363974
- Testing
- XIAP antisense
- Where
- 7 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Aegera Therapeutics
Acute Myeloid Leukemia
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and…
- Trial name
- NCT02834390
- Testing
- Quizartinib, Cytarabine, Idarubicin
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Coronary Disease, Heart Diseases
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- BIOMAG-III (NCT07258290)
- Testing
- Freesolve RMS, Xience DES
- Where
- 3 sites in United States, Latvia
- Volunteers
- 1,859 people
- Sponsor
- Teleflex
Acute Myeloid Leukemia, Essential Thrombocythemia
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
The purpose of this study is to determine a safe dose of LY573636-sodium to be given to patients with acute myeloid leukemia and to determine any side effects that may be associated with LY573636-sodium in this patient…
- Trial name
- NCT00718159
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company